Patents Assigned to Sandoz AG
  • Patent number: 10842782
    Abstract: The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: November 24, 2020
    Assignee: Sandoz AG
    Inventors: Franz Xaver Schwarz, Arthur Pichler
  • Publication number: 20200290995
    Abstract: The invention relates to acid addition salts of ridinilazole and processes for the preparation of ridinilazole using these acid addition salts. In addition, the present invention relates to processes for the preparation of ridinilazole in pure form using acid addition salts of ridinilazole as process intermediates.
    Type: Application
    Filed: July 27, 2018
    Publication date: September 17, 2020
    Applicant: Sandoz AG
    Inventors: Erwin Schreiner, Sven Nerdinger, Gerhard Laus
  • Patent number: 10775384
    Abstract: The present invention deals with a method for detecting a protein in a protein sample by amplifying and enhancing small differences between proteins contained in the protein sample. In particular, the present invention uses a cascade of enzymatic modification steps to detect and identify a protein in a protein sample by enhancing small differences between the protein and other proteins contained in the protein sample. Further, the present invention provides a method for distinguishing two proteins having substantially identical or similar amino acid sequences but different protein conformations.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: September 15, 2020
    Assignee: Sandoz AG
    Inventors: Hans Brandstetter, Julia Hollerweger
  • Patent number: 10752930
    Abstract: A method for producing a protein of interest on a manufacturing scale is based on integration, by homologous recombination, of the DNA encoding the protein of interest into a bacterial cell's genome at a pre-selected site. The manufacturing scale production of recombinant proteins is in the fed-batch mode, semi-continuous or in a chemostat.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: August 25, 2020
    Assignees: Boehringer Ingelheim RCV GmbH & Co KG, Sandoz AG
    Inventors: Gerald Striedner, Johann Huber, Daniela Reinisch
  • Publication number: 20200262792
    Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
    Type: Application
    Filed: July 11, 2018
    Publication date: August 20, 2020
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich
  • Patent number: 10711276
    Abstract: Amino acid residue misincorporations are necessarily found in sequence variants at low concentrations in admixture with expressed polypeptides, resulting from one or more base mismatches within codons susceptible to amino acid residue misincorporation during transcription and/or translation. The invention provides a method of optimizing the coding sequences of a polynucleotide that encodes a polypeptide, wherein at least one codon is susceptible to amino acid residue misincorporation. The method of the invention can be used to reverse-engineer an unknown coding sequence, which encodes the same polypeptide, but differs in said at least one codon from the known coding sequence. The method can further be used to alter the immunogenic potential of an expressed polypeptide. Thus, the invention is useful in engineering optimized polynucleotides encoding polypeptides.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 14, 2020
    Assignee: Sandoz AG
    Inventors: Johann Holzmann, Michael Fuchs, Clemens Achmüller, Hansjörg Toll
  • Patent number: 10711279
    Abstract: The present invention relates to new promoter sequences and uses thereof, in particular expression cassettes, vectors, and methods of expressing genes using the new promoters.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: July 14, 2020
    Assignee: SANDOZ AG
    Inventors: Wolfgang Ernst, Jens Pontiller, Friedemann Hesse, Haruthai Thaisuchat
  • Patent number: 10703750
    Abstract: The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in the treatment of hyperkinetic disorders, and methods for obtaining such forms.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 7, 2020
    Assignee: Sandoz AG
    Inventors: Christoph Langes, Stefan Reissmann
  • Publication number: 20200199070
    Abstract: The invention relates to crystalline eravacycline bis-hydrochloride and to a process for its preparation. Furthermore, the invention relates to the use of crystalline eravacycline bis-hydrochloride for the preparation of pharmaceutical compositions. The invention further relates to pharmaceutical compositions comprising an effective amount of crystalline eravacycline bis-hydrochloride. The pharmaceutical compositions of the present invention can be used as medicaments, in particular for treatment and/or prevention of bacterial infections e.g. caused by Gram negative pathogens or Gram positive pathogens, in particular caused by multidrug resistant Gram negative pathogens. The pharmaceutical compositions of the present invention can thus be used as medicaments for e.g.
    Type: Application
    Filed: January 20, 2017
    Publication date: June 25, 2020
    Applicant: Sandoz AG
    Inventor: Hannes Lengauer
  • Publication number: 20200179288
    Abstract: The present invention refers to pellets comprising pharmaceutically active ingredient and binder. Further, the invention refers to a process for preparing said pellets, to the use of said pellets for preparing a pharmaceutical composition, and to a dosage form comprising said pellets or pharmaceutical composition. Finally, the present invention refers to a dosage from for use in a method of treating a disease selected from the group consisting of gastro esophageal reflux disease, peptic ulcer disease, and Zollinger-Ellison syndrome and for prevention of upper gastrointestinal bleeding in people who are at high risk.
    Type: Application
    Filed: September 5, 2017
    Publication date: June 11, 2020
    Applicant: Sandoz AG
    Inventors: Rok Staric, Bostjan Petek
  • Patent number: 10661264
    Abstract: The present invention provides novel methods of cell disruption and release of biomolecules from a cell. The invention comprises the use of positively and/or negatively charged microparticles comprising ground resin. It is particularly useful for purification of biomolecules from cell culture.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: May 26, 2020
    Assignees: BOEHRINGER INGELHEIM RCV GMBH & CO KG, SANDOZ AG
    Inventors: Rainer Hahn, Alois Jungbauer, Alexandru Trefilov
  • Publication number: 20200102297
    Abstract: The present invention relates to a polymorphic form of masitinib mesylate, processes for its preparation, pharmaceutical compositions comprising it and their medical use.
    Type: Application
    Filed: March 22, 2018
    Publication date: April 2, 2020
    Applicant: Sandoz AG
    Inventors: Nolwenn Martin, Diana Fischer-Daut
  • Patent number: 10576065
    Abstract: The present invention relates to a pharmaceutical composition containing rifaximin in the form of two different polymorphs as well as a method of preparing the same.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: March 3, 2020
    Assignee: Sandoz AG
    Inventor: Johannes Raneburger
  • Publication number: 20200062750
    Abstract: The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia.
    Type: Application
    Filed: February 1, 2018
    Publication date: February 27, 2020
    Applicant: Sandoz AG
    Inventors: Christoph Langes, Ulrich Griesser, Erwin Schreiner, Marijan Stefinovic
  • Publication number: 20200022980
    Abstract: The invention relates to an amorphous solid dispersion comprising elagolix sodium and at least one silicon-based inorganic compound and to a process for preparing the same. Furthermore, it relates to a pharmaceutical composition comprising said solid dispersion and one or more additional pharmaceutical acceptable excipient(s), wherein the pharmaceutical composition can be used as a medicament, in particular for the treatment of endometriosis and uterine fibroids.
    Type: Application
    Filed: April 11, 2018
    Publication date: January 23, 2020
    Applicant: Sandoz AG
    Inventor: Nolwenn Martin
  • Patent number: 10537887
    Abstract: The present invention provides a novel adsorbent composition for recovering biomolecules from a fluid. The composition comprises positively and negatively charged microparticles in the form of ground particles. The adsorbent is particularly useful for purification of biomolecules from the cell culture.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: January 21, 2020
    Assignees: BOEHRINGER INGELHEIM RCV & GMBH CO KG, SANDOZ AG
    Inventors: Rainer Hahn, Alois Jungbauer, Alexandru Trefilov, Moritz Imendoerffer
  • Patent number: 10532058
    Abstract: The present invention relates to a highly convergent method for the synthesis and purification of ceftolozane and intermediates starting from 7-aminocephaiosporanic acid (7-ACA).
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: January 14, 2020
    Assignee: Sandoz AG
    Inventors: Michael Fischer, Wolfgang Felzmann, Ronny Huetz, Martin Langner, Birgit Endl
  • Publication number: 20190388404
    Abstract: The present invention relates to an oral dosage form containing rifaximin in form beta, wherein the oral dosage form provides delayed release of the active pharmaceutical agent. Further, the invention relates to the preparation of an oral dosage form, preferably a tablet.
    Type: Application
    Filed: April 25, 2018
    Publication date: December 26, 2019
    Applicant: Sandoz AG
    Inventor: Franz Xaver Schwarz
  • Publication number: 20190381085
    Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 19, 2019
    Applicant: Sandoz AG
    Inventor: Nolwenn Martin
  • Patent number: RE47787
    Abstract: The present invention relates to a novel process for preparing ceftaroline fosamil as well as to intermediates of this process.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: December 31, 2019
    Assignee: Sandoz AG
    Inventors: Hubert Sturm, Josef Wieser